AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed
Stem Cell Therapies for Demyelinating Diseases: Systematic Review
A systematic review found that autologous hematopoietic stem cell transplantation (AHSCT) is the most supported therapy for highly active relapsing MS, primarily aiding through immune system reconstitution. In contrast, mesenchymal stromal cell (MSC) methods remain investigational due to unresolved efficacy and safety issues, while avenues such as MSC-derived extracellular vesicles and iPSC-derived products are still in preclinical stages.
What this does not proveThe review does not provide specific clinical trial results, and numerous factors, such as product heterogeneity and safety concerns, limit the translation of these therapies into clinical practice.